Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma-Reference-Cited by-同舟云学术

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma

Published:2019-03-22 Issue:2 Volume:106 Page:383-390
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Chia Yen Lin¹,Yan Li¹,Yu Binbing²,Wang Bing¹,Barker Peter³,Goldman Mitchell³,Roskos Lorin²

Affiliation:

1. MedImmune LLC South San Francisco California USA

2. MedImmune LLC Gaithersburg Maryland USA

3. AstraZeneca Gaithersburg Maryland USA

Funder

MedImmune

AstraZeneca

Kyowa Hakko Kirin

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1371

Reference14 articles.

1. MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

2. FASENRA™ (benralizumab) prescribing information November 2017 . Accessed December 12 2017.

3. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma

4. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

5. Exposure‐response analysis for determination of benralizumab optimal dosing regimen in adults with asthma;Wang B.;Am. J. Respir. Crit. Care Med.,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of biologics used in the treatment of asthma;Human Antibodies;2024-07-24

2. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment;Advances in Pharmacology;2023

3. Efficacy and safety of treatment with benralizumab for eosinophilic asthma;International Immunopharmacology;2022-10

4. Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma;Annals of Allergy, Asthma & Immunology;2022-05

5. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions;Respiratory Research;2021-06-07